Tarlatamab for recurrent gynecological neuroendocrine cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new drug, Tarlatamab, for women whose gynecological neuroendocrine cancer has come back or spread. The drug targets a protein on cancer cells to help the immune system attack them. The study aims to see if it can shrink tumors and slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed high-grade neuroendocrine carcinoma of the cervix, vulva, or vagina, or a small cell cervical cancer.
- You have already had platinum-based chemotherapy (like cisplatin or carboplatin) for your cancer.
- Your cancer has gotten worse despite your most recent treatment.
- You are generally well enough to carry out daily activities (ECOG performance status 0, 1, or 2).
- You have at least one tumor that can be measured on a scan.
- You can provide a tissue sample from your tumor (either from a past biopsy or willing to have a new one) for research.
- Your heart, liver, and kidney function are adequate, and you have no significant fluid around the lungs.
- You have recovered from side effects of previous treatments.
- You are willing to use effective contraception if you can become pregnant.
- You are not on any other cancer treatment within 2 weeks of starting the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called tarlatamab for people with a rare cancer called extrapulmonary neuroendocrine carcinoma that has grown or returned after standard chemotherapy. The goal is to see if tarlatamab can help shrink tumors and improve outcomes.
This trial tests a new drug called tarlatamab for people with advanced small cell or neuroendocrine cancers that started outside the lung (like in the stomach, bladder, or head and neck) and have grown after initial chemotherapy. It aims to see if this treatment can shrink or control the cancer.
This trial tests a new drug, tarlatamab, for people with small cell lung cancer that has spread to the brain. It aims to see if the drug can shrink brain tumors and help you live longer, especially if you have not had brain radiation before.
This trial tests a new drug, tarlatamab, which targets a protein called DLL3 found on the surface of certain cancer cells. The goal is to see if it can shrink or control tumors in people with small-cell lung cancer or other poorly differentiated neuroendocrine cancers, and to learn more about who benefits most.
This trial tests an experimental drug called tarlatamab for people newly diagnosed with extensive-stage small-cell lung cancer (SCLC). The goal is to see if tarlatamab can help shrink or control the cancer.
This trial tests a drug called tarlatamab for people with advanced prostate cancer that has a specific protein (DLL3) on their tumor cells. The goal is to see if tarlatamab can help shrink or slow the cancer.
Hear when a new Diagnosis of Neuro-endocrine Carcinoma of the Gynecological Tract trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.